Dingbang Bio Secures Tens of Millions RMB in Angel Funding to Advance Stable Isotope Drug Development

VCBeat has learned at the earliest opportunity,Shenzhen Dingbang Biotechnology Co., Ltd.(hereinafter referred to as"Dingbang Biotech") recently obtainedYanghe InvestmentExclusively InvestedTens of millions of yuan in angel round financing, the funds will be used for R&D investment and technological innovation.

Dingbang was established in August 2019 and is a company dedicated toA biopharmaceutical and medical device enterprise integrating the R&D, production, sales, and services of stable isotope drugs.. The company operates drug synthesis and drug analysis laboratories, equipped with advanced instruments such as HPLC, GC/MS, and UPLC/MS.

Dingbang Biotech's drugs under development are mainly composed of²H、¹⁰B、¹³C、¹⁸O-labeled stable isotope drugs, among which²Deuterium (²H) is classified as a medical imaging agent, applied in clinical magnetic resonance (MR) molecular metabolic imaging. It enables not only in vivo quantitative analysis but also early screening and diagnosis of cancers (such as metabolic tumors including hepatocellular carcinoma and glioma) and neurodegenerative diseases. The field to which it belongs, Deuterium Metabolic Imaging (DMI), represents a new generation of non-invasive, ultra-high-field, multi-nuclear MR molecular diagnostic technology and constitutes a core clinical application for future strategic deployment by major imaging equipment manufacturers such as “GPS” (GE Healthcare, Philips, and Siemens Healthineers).¹⁰B (boron) is applied in BNCT technology (boron neutron capture therapy).¹³C (Carbon) Applied to¹³C-UBT Breath Test Diagnostic Technology and 13C Magnetic Resonance Technology,¹⁸O (oxygen) is applied in PET-CT precursor synthesis and synthesis modules. Currently, some core products have completed preclinical studies and are preparing to enter the IND stage.

Commercialization-wise, based onFounder: Yang XiaojunLeveraging its founder’s background in nuclear physics from the University of Science and Technology of China, along with continuous entrepreneurial experience and accumulated resources, the company has not only pursued independent innovative drug R&D but also expanded into services such as CMC reference standard quality research, CNAS-accredited third-party drug testing, and magnetic resonance molecular imaging CRO, thereby initially achieving self-sustaining operational capability.

Regarding this round of financing,Dingbang BiotechCo-Founder Ruan Yinghengstated: “We extend our gratitude to investors, including Yanghe Investment, for their recognition and support of Dingbang Bio. The research and development of stable isotope drugs is a multidisciplinary field involving core commercial barriers such as isotope distillation, drug synthesis, and nuclear magnetic resonance (NMR) applications. We will redouble our efforts to drive the company’s rapid overall growth.”

Fu Chao, Vice President of Yanghe Investment“The field of stable isotopes holds immense promise. Beyond 13C, other isotopes such as 18O, 10B, and 2H are increasingly being adopted in both scientific research and clinical applications. The application of stable isotopes lies at the intersection of pharmaceuticals and medical devices, requiring integrated R&D capabilities and resource coordination across multiple disciplines, as well as exploration of their use in emerging areas. The Dingbang Biotechnology team demonstrates keen market insight, strong execution capability, and extensive accumulated experience. We are honored to invest in Dingbang Biotechnology and will support its growth into a benchmark enterprise in the stable isotope industry.”

Yanghe Investment, founded in 2013, is a China-based industrial investment firm specializing in niche sectors of the healthcare industry. It focuses primarily on medical technologies, innovative medical devices, and healthcare services, with its portfolio concentrated in early-to-mid-stage companies. Adhering to a long-term strategy of uncovering investment opportunities through in-depth research of niche segments, the firm empowers its portfolio companies and achieves its own growth by fostering the development of its investments. Since its inception, Yanghe Investment has invested in numerous high-quality healthcare enterprises, including Vishee Medical, Mingkang Medical, Libo Pharmaceutical, Kanglu Biotechnology, Nuoer Medical, Ruitong Biotechnology, and RaisePharm.